Best Vitamin K2 Supplements Ranked 2026
Last updated: March 2026 · Evidence-based ranking
Vitamin K2 is the unsung cofactor that determines where calcium goes in your body — into bones and teeth, or into arterial walls. If you supplement vitamin D3 or calcium, K2 is not optional. This ranking covers the two clinically relevant forms (MK-7 and MK-4), why the half-life difference matters, and how to dose K2 for cardiovascular, bone, and longevity outcomes.
⚡ TL;DR
- • Best daily form: MK-7 (all-trans menaquinone-7), 100–200 mcg/day
- • Key job: Activates Matrix Gla Protein (arterial calcification) + osteocalcin (bone mineralization)
- • Must-pair: Take with vitamin D3 and fat-containing meal
- • Cardiovascular data: VitaK-CAC trial — 180 mcg/day MK-7 slowed calcification 50% over 2 years
- • Warfarin users: Do NOT supplement without physician oversight
- • Biomarkers: dp-ucMGP (vascular) and ucOC (bone) for status testing
Vitamin K2 Forms Ranked by Clinical Evidence
#1 — MK-7 (All-Trans Menaquinone-7), Natto-Derived
Best ChoiceThe gold standard for daily supplementation. Half-life of 72 hours means once-daily dosing maintains stable carboxylation of both MGP and osteocalcin. Derived from natto fermentation; the all-trans isomer is the biologically active form — avoid synthetic MK-7 with high cis-isomer content. Widely studied at 100–200 mcg/day for cardiovascular and bone endpoints. Low dose, high efficacy.
#2 — D3 + MK-7 Combination Capsule
Best StackPairing D3 with MK-7 in a single oil-based softgel or capsule improves adherence and ensures the two cofactors are taken together — the D3/K2 relationship is one of the strongest and most clinically important pairings in nutritional medicine. The fat-based delivery matrix also improves absorption of both fat-soluble vitamins simultaneously. Look for 2,000–5,000 IU D3 with 100–200 mcg MK-7.
#3 — MK-4 (Menaquinone-4), Standard Dose 100–500 mcg
Use Case SpecificShort half-life (1–2 hours) requires 3× daily dosing to maintain tissue levels. Most animal-based food K2 is MK-4. At supplemental doses (100–500 mcg), MK-4 can complement MK-7 coverage — MK-4 appears to have distinct tissue distribution (brain, pancreas) compared to MK-7 (liver, arterial wall, bone). Some practitioners use both forms for broader coverage. Clinical bone trials used pharmacological MK-4 (45 mg/day, 3×15 mg doses) — far beyond typical supplements.
#4 — MK-9 (from Natto or Cheese)
Dietary OnlyMK-9 is found in fermented cheeses (especially Gouda) and contributes to the cardiovascular benefit seen in high dairy-fat consumers in the Rotterdam Study. Not commercially available as a standalone supplement — the K2 benefit from cheese comes as a mixture of MK-8, MK-9, and MK-10. If you eat Gouda or aged fermented cheeses regularly, you are getting modest MK-9 intake. Don't supplement specifically for MK-9; cover bases with MK-7 and eat aged cheese if desired.
⚠️ Avoid — Vitamin K1 (Phylloquinone) for K2 Goals
K1 (phylloquinone, found in leafy greens) primarily supports hepatic clotting factor carboxylation and has minimal activity at extrahepatic sites like arterial walls and bones. The body converts a small fraction of K1 to MK-4 via the menadione pathway, but this conversion is inefficient and insufficient to achieve the cardiovascular and bone benefits seen with direct MK-7 supplementation. Many cheap multivitamins contain only K1 — this does not substitute for K2.
How K2 Works: Carboxylation Targets
K2 is a cofactor for gamma-glutamyl carboxylase — the enzyme that activates vitamin K-dependent proteins (VKDPs) by adding a carboxyl group to glutamic acid residues. Without adequate K2, these proteins remain undercarboxylated and non-functional.
| Protein | Location | Function When Carboxylated | Consequence When Undercarboxylated |
|---|---|---|---|
| Matrix Gla Protein (MGP) | Arterial wall, cartilage | Inhibits calcium crystal deposition in vessel walls; prevents vascular calcification | Arterial calcification; atherosclerotic plaque progression; arterial stiffness |
| Osteocalcin (OC) | Bone matrix | Binds hydroxyapatite crystals; anchors calcium into bone; regulates bone density | Reduced bone mineral density; higher fracture risk; calcium deposited elsewhere |
| Coagulation Factors II, VII, IX, X | Liver | Normal clotting cascade activation | Bleeding risk (warfarin mechanism targets this pathway) |
| Protein S and Protein C | Plasma, endothelium | Anticoagulant regulation; prevents excessive clotting | Increased thrombosis risk; paradoxical clotting when warfarin started |
| Gas6 (Growth Arrest-Specific 6) | Nervous system, vasculature | Cell survival signaling; phagocytosis; platelet activation regulation | Impaired vascular homeostasis; under investigation for neurological roles |
| Periostin | Bone periosteum, heart valves | Bone cortical formation; heart valve integrity | Reduced bone structural quality; valve calcification risk |
K2 Dosing by Goal
| Goal | Recommended Form | Dose | Evidence Basis |
|---|---|---|---|
| General prevention (D3 users) | MK-7 | 100–120 mcg/day | Observational; mechanistic cofactor requirement |
| Cardiovascular calcification prevention | MK-7 | 180 mcg/day | VitaK-CAC Trial (2015, RCT) |
| Bone density support (osteopenia) | MK-7 | 150–200 mcg/day + D3 + calcium | Multiple bone RCTs; osteocalcin carboxylation data |
| High-dose D3 protocol (>5,000 IU) | MK-7 + MK-4 | 200 mcg MK-7 + 200–500 mcg MK-4 | Higher D3 → more calcium absorbed → higher K2 requirement |
| Calcium supplement users | MK-7 | 100–180 mcg/day | Calcium supplementation raises calcification risk without K2 |
| Menopause / post-menopausal bone | MK-7 | 180–200 mcg/day | Japanese menopausal RCTs; Knapen 2013 |
| Broad longevity / healthy aging stack | MK-7 + dietary MK-9 (cheese) | 100 mcg MK-7 + 30g aged Gouda daily | Rotterdam Study dietary pattern data |
MK-7 vs. MK-4: Head-to-Head
| Factor | MK-7 | MK-4 |
|---|---|---|
| Serum half-life | ~72 hours | 1–2 hours |
| Dosing frequency | Once daily | 2–3× daily for stability |
| Supplemental effective dose | 100–200 mcg | 100–500 mcg (supplement); 45 mg (therapeutic) |
| MGP carboxylation (arterial) | Strong — hepatic + extrahepatic | Moderate at supplement doses |
| Osteocalcin carboxylation (bone) | Strong | Strong (especially at pharmacological 45 mg/day) |
| Tissue distribution | Liver, arterial wall, bone | Brain, pancreas, kidney (distinct from MK-7) |
| Source | Natto fermentation (all-trans) | Animal foods; enzymatic conversion from K1 |
| Cardiovascular RCT evidence | Strong (VitaK-CAC; Rotterdam) | Minimal at supplement doses |
| Verdict | Best standalone supplement choice | Best as complement to MK-7 for brain/metabolic coverage |
K2 Cofactor Stack
| Cofactor | Why It Matters with K2 | Interaction Type |
|---|---|---|
| Vitamin D3 | D3 upregulates calcium absorption 2–4×; K2 determines where that calcium deposits (bone vs. arteries). The D3/K2 pair is foundational. | Synergistic — MUST pair |
| Calcium | K2 is required to direct supplemental calcium into bone via osteocalcin activation. Calcium supplementation without K2 increases soft-tissue calcification risk. | Synergistic — strongly recommended together |
| Magnesium | Activates D3 (25-OH-D → 1,25-OH-D2 conversion); also required for bone crystalline structure alongside calcium. Completes the D3/K2/Ca stack. | Synergistic cofactor |
| Vitamin A (Retinol) | Retinol and K2 co-regulate osteocalcin synthesis. Both are fat-soluble and interact via shared receptor pathways. Excess preformed vitamin A (retinol) can interfere with K2-dependent bone signaling. | Monitor: keep retinol ≤2,500 IU/day with high K2 |
| Dietary fat | K2 is fat-soluble — requires bile salts and dietary fat for absorption. Take with a meal containing fat (eggs, olive oil, avocado, nuts). | Absorption requirement |
| Warfarin / K-antagonists | Warfarin blocks vitamin K recycling (VKOR) — both K1 and K2 will counteract warfarin. Do NOT supplement K2 without physician oversight and INR monitoring. | Contraindication — requires MD supervision |
Who Needs K2 Supplementation
High-Need Groups
- • Vitamin D3 supplementers (>2,000 IU/day)
- • Calcium supplement users
- • Adults over 50 (reduced dietary K2 conversion)
- • Post-menopausal women (bone loss period)
- • Osteopenia / osteoporosis diagnosis
- • Cardiovascular risk (CAC score >0)
- • Low fermented food intake (no natto, aged cheese)
- • Crohn's disease / fat malabsorption conditions
- • Long-term PPI users (reduce fat-soluble vitamin absorption)
- • Anyone with elevated dp-ucMGP on bloodwork
Caution / Contraindication Groups
- • Warfarin users — consult MD first
- • Any vitamin K antagonist anticoagulant users
- • Hypercoagulable disorders (discuss with hematologist)
- • Severe liver disease (impaired fat-soluble vitamin metabolism)
- • Upcoming surgical procedures (discuss K2 timing)
Note: DOACs (apixaban, rivaroxaban) do NOT interact with K2 — only vitamin K antagonists do.
Key Clinical Evidence
VitaK-CAC Trial (2015)
Randomized controlled trial in 244 healthy adults aged 55+. 180 mcg/day MK-7 for 2 years vs. placebo. Result: Significant reduction in CAC score progression (~50% slower calcification) in the active arm. dp-ucMGP dropped significantly, confirming improved vascular MGP carboxylation. This is the primary RCT cited for K2 cardiovascular benefit.
Rotterdam Study (2004)
Prospective cohort, 4,807 adults over 7.2 years. Highest vs. lowest K2 intake tertile: 57% lower cardiovascular mortality, 52% lower severe aortic calcification, 26% lower all-cause mortality. K1 intake showed no cardiovascular association. This study established the K2/cardiovascular signal that drove subsequent mechanistic and interventional research.
Knapen et al. (2013)
RCT in 244 healthy post-menopausal women, 3 years. 180 mcg/day MK-7 vs. placebo. Result: Significant improvements in bone mineral density (lumbar spine, femoral neck) and bone strength indices vs. placebo. osteocalcin carboxylation improved significantly. Established MK-7 as evidence-based for bone outcomes in post-menopausal women.
Testing Your K2 Status
| Biomarker | What It Measures | Target / Interpretation | Availability |
|---|---|---|---|
| dp-ucMGP | Vascular K2 status — uncarboxylated Matrix Gla Protein in circulation | Low = good (sufficient K2). High = elevated cardiovascular/calcification risk. Target: below median for age | Specialty labs (e.g. VitaK BV, some functional medicine panels) |
| ucOC (undercarboxylated osteocalcin) | Bone K2 status — fraction of osteocalcin not carboxylated | Low ucOC = sufficient K2 for bone. High ucOC = bone K2 deficiency. %ucOC <20% generally adequate | Specialty bone labs; some hormone panels include it |
| Total osteocalcin | Bone turnover marker (carboxylated + undercarboxylated) | Context-dependent: elevated in high turnover states; interpret alongside ucOC ratio | Available at most bone specialty labs |
| DEXA T-score (bone) | Bone mineral density vs. young adult reference | Normal: >-1.0 | Osteopenia: -1.0 to -2.5 | Osteoporosis: <-2.5 | Radiology; ordered by PCP or OB/GYN |
| CAC Score (CT scan) | Coronary artery calcification — direct imaging of arterial calcium deposits | 0 = no calcification; 1–100 = mild; >400 = severe. K2 interventions target slowing progression | Cardiologist; dedicated CAC CT centers; ~$100–200 |
5 Common K2 Mistakes
Multivitamins listing "Vitamin K 80 mcg" almost always mean K1 (phylloquinone). K1 does not meaningfully activate MGP or osteocalcin at these doses. Check your label for "Vitamin K2" or "Menaquinone-7 (MK-7)."
K2 is fat-soluble. Absorption drops dramatically when taken fasted or with fat-free meals. Take with at least 10g of dietary fat — eggs, olive oil, nuts, avocado, or full-fat dairy.
High-dose D3 dramatically increases calcium absorption. Without K2, that calcium has nowhere to go but soft tissues. This is the most important K2 use case for most supplement users.
Synthetic MK-7 production can yield up to 50% inactive cis-isomers. Only the all-trans MK-7 isomer is biologically active. Natto-fermentation derived MK-7 is predominantly all-trans. Check for "all-trans" or "≥97% all-trans" on the label or COA.
K2 must be taken consistently alongside D3 and calcium supplementation to maintain MGP and osteocalcin carboxylation. Discontinuing K2 while continuing D3/calcium creates the exact imbalance it was meant to prevent.
Frequently Asked Questions
What is the best form of vitamin K2?
MK-7 (menaquinone-7) is the top-ranked form for daily supplementation. Its 72-hour half-life allows once-daily dosing, and it activates both osteocalcin (bone) and Matrix Gla Protein (arterial calcification prevention) at clinically studied doses of 100–200 mcg/day. Look for all-trans MK-7 derived from natto fermentation.
How much vitamin K2 MK-7 should I take per day?
The most studied dose is 100–200 mcg/day. The VitaK-CAC cardiovascular trial used 180 mcg/day. For bone support, 100–150 mcg/day is commonly used. Take with a fat-containing meal for best absorption.
Do I need vitamin K2 if I take vitamin D3?
Yes. D3 increases calcium absorption 2–4×. Without sufficient K2, that calcium can deposit in arteries rather than bones. K2 activates Matrix Gla Protein to prevent vascular calcification. Anyone supplementing D3 >2,000 IU/day should strongly consider pairing with K2 MK-7.
Can vitamin K2 reverse arterial calcification?
The VitaK-CAC Trial (2015) showed 180 mcg/day MK-7 slowed CAC progression by ~50% over 2 years. Some observational data suggests possible regression. The Rotterdam Study found the highest K2 intake quartile had 57% lower cardiovascular death risk. Slowing progression is well-supported; full reversal is less established but mechanistically plausible.
Is vitamin K2 safe with blood thinners like warfarin?
No — do NOT supplement K2 with warfarin without physician supervision and frequent INR monitoring. K2 competes with warfarin's mechanism (VKOR pathway). Note: newer DOACs (apixaban, rivaroxaban) have a different mechanism and are not affected by K2.
MK-7 vs. MK-4: which is better for bones?
Both activate osteocalcin. MK-7 at 100–200 mcg/day achieves this at practical supplement doses. MK-4 bone data comes from pharmacological doses (45 mg/day — 450× higher). For supplementation, MK-7 wins on dose efficiency. For complementary tissue coverage (brain, pancreas), adding low-dose MK-4 alongside MK-7 is a valid stack.
Can I get enough K2 from food?
Natto delivers ~1,000 mcg K2 per 100g (primarily MK-7). Aged cheeses (Gouda, Brie) provide 10–75 mcg per 100g as MK-4/MK-9. Most Western diets provide <10 mcg/day MK-7. Supplementation is justified for most adults not eating natto regularly, especially D3 or calcium users.
What is dp-ucMGP and ucOC in bloodwork?
dp-ucMGP (dephospho-uncarboxylated MGP) measures vascular K2 status — high dp-ucMGP means insufficient K2 for arterial protection and independently predicts cardiovascular events. ucOC (undercarboxylated osteocalcin) measures bone K2 status — high ucOC means inadequate bone mineralization signaling. Both require specialty labs; target low values for both.
Related Rankings
- Best Vitamin D3 Supplements Ranked 2026 — The essential K2 pairing partner
- Best Calcium Supplements Ranked 2026 — Requires K2 for safe, targeted bone deposition
- Best Magnesium Supplements Ranked — Activates D3; completes the bone/cardiovascular stack
- Best Anti-Aging Supplements for Women Ranked 2026 — K2 is foundational for post-menopausal bone and arterial health
- Best Multivitamins Ranked 2026 — Most multivitamins contain K1 only; check for MK-7
- Best Omega-3 Supplements Ranked 2026 — Pairs with K2 in cardiovascular longevity protocols
Build Your Full Bone + Cardiovascular Stack
The D3 + K2 + Magnesium + Calcium quartet is one of the most evidence-backed supplement stacks in longevity medicine. See all four ranked protocols.
Get New Protocol Rankings First
Subscribe for weekly protocol breakdowns, ranking updates, and evidence-based implementation guides.
No spam. No hype. Unsubscribe any time.